TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05275543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paro Robot
Description: Device: PARO therapy seal PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paro Robot
Description: Device: PARO therapy seal PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
Study: NCT06095882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Study group: Acupuncture treatment was performed from day 3 to day 14 after surgery. Points include: Zhongwan, Tianshu, Watercourse, Taichong, Sanyinjiao, Zusanli, Yin Lingquan.~Control group: No intervention, the urinary tube was removed until the 14th day after surgery. Patients with urinary retention may receive further acupuncture treatment.
Study: NCT05130216

Intervention type: OTHER
Intervention: Genicular Nerve Radiofrequency Ablation
Description: Radiofrequency Ablation (RFA)
Study: NCT05014295

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Accessing personal medical records online via online portals
Description: The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
Study: NCT06232915

Intervention type: PROCEDURE
Intervention: Mechanical ventilation
Description: Mechanical ventilation during surgery
Study: NCT04648228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT+MBRP
Description: Intervention is behavioral treatment group that combines Acceptance and Commitment Therapy (ACT) with Mindfulness-Based Relapse Prevention. The group focuses on living with long-term pain, ways to complete daily living activities when you experience pain, coping with opioid and other drug cravings, and training in mindfulness practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education control
Description: Education control is behavioral treatment group that combines pain patient education with opioid and other drug education. The group focuses on experiences of long-term pain, instructions on how to function with this pain, and facts about opioids and other drugs.
Study: NCT05852262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: 1000 mg PO QID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: 500 mg PO QID plus oral placebo for 7 days
Study: NCT05566444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat stimulus
Description: Contact heat pain stimulus with a termode set at 46 degrees and contact warm stimulus with a termode set at 40 degrees
Study: NCT06415955

Intervention type: OTHER
Intervention: None, pure observationnal study
Description: None, pure observationnal study
Study: NCT05634746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo orally disintegrating tablet.~Other Names:~PBO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
Study: NCT06045416

Intervention type: PROCEDURE
Intervention: venous blood puncture
Description: Venous blood puncture performed at first hospital contact, and at 28 days, 3 month, and 6 months after hospital admission.~Lumbar puncture and joint puncture for the study will be performed if it is indicated due to diagnostic or therapeutic reasons.

Intervention type: PROCEDURE
Intervention: venous blood puncture
Description: Venous blood puncture performed at first hospital contact, and at 28 days, 3 month, and 6 months after hospital admission.~Lumbar puncture and joint puncture for the study will be performed if it is indicated due to diagnostic or therapeutic reasons.
Study: NCT04906720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: colchicine 0.6mg oral twice daily for 7 days
Study: NCT06012448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.~In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks.
Study: NCT06387966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flunotinib
Description: Day one will be used for drug administration, and Day two\~Day seven will be used for experimental data collection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: flunotinib placebo
Description: Day one will be used for drug administration, and Day two\~Day seven will be used for experimental data collection.
Study: NCT04642898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard UP Treatment
Description: Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard UP Treatment
Description: Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capitalization UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capitalization UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensation UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensation UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
Study: NCT06350669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation phone application
Description: The standard vestibular rehabilitation process, with the support of a phone app throughout the process
Study: NCT05232864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: 300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)
Study: NCT06304883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: ALZ-801
Description: ALZ-801 265 mg BID tablet orally.
Study: NCT04634916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoAVF Creation
Description: Subjects will have an endoAVF created using the WavelinQ EndoAVF System
Study: NCT05862129

Intervention type: PROCEDURE
Intervention: surgical operation
Description: Radical operation for the perianal abscess
Study: NCT05770934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restricted low-load resistance exercise
Description: Blood flow restricted low-load resistance exercise
Study: NCT04796792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Break Wave Lithotripsy and Ultrasonic Propulsion
Description: Novel ultrasound technologies to facilitate passage of stones.This includes Burst Wave Lithotripsy (BWL), a technology to noninvasively fragment urinary calculi within the kidney and ureter, and ultrasonic propulsion, a technology to non-invasively reposition stones within the kidney and ureter. BWL uses short multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. Ultrasonic propulsion uses long multi-cycle bursts of low amplitude ultrasound to move stones within the collecting system.
Study: NCT05555901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib+ chemotherapy
Description: Second-line treatment : Fruquintinib+FOLFIRI Drug: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off, q4w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Fruquintinib+Capecitabine Drug: Fruquintinib 4mg, orally, once daily, 2 weeks on/ 1 week off, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab+ chemotherapy
Description: Second-line treatment : Bevacizumab+FOLFIRI Drug: Bevacizumab 5mg/kg on day 1, q2w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Bevacizumab+Capecitabine Drug: Bevacizumab 7.5mg/kg on day 1, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w
Study: NCT06511089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carotid artery stenting during EVT
Description: Patients with an ipsilateral high grade carotid artery stenosis or occlusion of presumed atherosclerotic origin and an proximal intracranial large vessel occlusion in the anterior circulation will be randomized using a web-based randomization tool to immediate carotid artery stenting or deferred treatment strategy of carotid artery stenosis.~In the intervention group, the cervical carotid artery lesion will be treated with a stent during the EVT (just before or directly after intracranial thrombus removal), the control group will be treated according to the national guidelines with carotid endarterectomy of carotid artery stenting (for patients with non-disabling stroke) or medical management alone (for patients with severe disabling stroke).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no carotid artery stenting during EVT
Description: A deferred treatment approach: carotid revascularization within two weeks after stroke onset or best medical management only, depending on the functional recovery of the patient.
Study: NCT06635759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper trapezius low-load endurance exercise
Description: Participants in the EE group will perform the overhead shrug exercise for the affected side using a green Thera-Band Elastic Band. To perform this exercise, the subject will stand and place one arm of the affected side in an overhead position against the wall. The middle portion of the theraband will be placed on the floor, and the subject will stand on the middle portion of the theraband to fixate it in place with both feet shoulder-width apart. Then, the subject grasp both tails of the theraband and perform the shoulder shrug movement for the affected side with a 3-second elevation, hold at the end range for 5 seconds, and then return back to the starting position with a 3-second depression. The subject will perform this exercise for 20 repetitions per set, 3 sets a day with 1-minute rest between sets, 3 alternate days a week, for 5 weeks. They will be instructed to record all training sessions in a diary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper trapezius stretching exercise
Description: Participants in the SE group will perform static upper trapezius stretching exercise for the affected side. To perform the stretch, participants will be asked to sit upright on a chair and look straight ahead. To reduce scapular elevation and upward rotation, the ipsilateral hand should be placed below the buttock. The subject will then be asked to perform deep neck flexion, neck rotation towards the affected side, and contralateral side flexion using the opposite hand in a diagonal direction until the position of 'mild discomfort' is attained. They should maintain the deep neck flexion when performing the stretch. The stretch will be held for 30 seconds each set, 3 sets a day, daily for 5 weeks.
Study: NCT04934033

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological assessments
Description: The participants will have a MRI, and language and cognitive assessments.
Study: NCT04660799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab IV
Description: Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m\^2 (milligram per square meter).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).
Study: NCT05360706

Intervention type: GENETIC
Intervention: AAV5-hFIX
Description: AAV5 containing a codon-optimized human factor IX gene
Study: NCT05230225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Notification Letter
Description: Receiving the electronic Physician Notification Letter to highlight echocardiography results that are consistent with or may be consistent with severe AS and to be reminded of ACC/AHA Clinical Practice Guideline recommendations regarding the management of severe AS.
Study: NCT05171608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-based protocol based fluid therapy
Description: Protocol of the interventional group according to the ultrasonographic findings:~Ultrasound scan 2 hours before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate intravenous (IV) fluid therapy: 8 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.~A 2nd ultrasound scan at 30 minutes before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate further IV fluid therapy: 5 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.
Study: NCT04660799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab IV
Description: Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m\^2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin will be administered IV at a dose of 50 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered IV at a dose of 50 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine will be administered IV at a dose of 1.4 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered IV at a dose of 1.4 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered orally at a dose of 100 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally at a dose of 100 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine hydrochloride or alternative antihistamine
Description: All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride or alternative antihistamine
Description: All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab
Study: NCT05404997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Therapy
Description: Subjects in Group A will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes. After the conventional therapy, this group will be given shockwave therapy treatment twice a week for four weeks.~After exposing and cleaning the treated area with alcohol, adequate amount of gel will be placed on the lower back region, and the machine will be adjusted at (2000 shock per session, 8 sessions 2 per week for 4 weeks, energy flux density 0,18mJ per mm square, 2 bars of pressure, frequency 10hz), with using 20mm D-Actor head.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland's lumbar mobilizations
Description: Subjects in Group B will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes.~After the conventional treatment, Group B will be given Maitland's lumbar postero-anterior glide mobilizations initiating from Grade 1, with 3-4 sets of oscillations of 40 counts in each set, 2 sets of oscillations will be given below and above the affected joint level.This whole mobilization treatment will also be given twice a week for 10 minutes.
Study: NCT05403450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolinapant
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine + Cedazuridine
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine + Cedazuridine
Description: Tablet for oral administration
Study: NCT05785715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-13 250mg
Description: NX-13 250mg tablet, plus 2 placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-13 750mg
Description: NX-13 250mg tablets times 3 to equal 750mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NX-13 Placebo
Description: NX-13 Placebo tablets times 3 for blinding purposes
Study: NCT06120231

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse width modulation
Description: Will be stimulating the pedicle screws utilizing three different pulse-width settings, 0.4 milliseconds, 0.2 milliseconds, and 0.05 milliseconds.
Study: NCT05515757

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile-app based contingency management
Description: We are adapting an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with stimulant use disorders requiring prolonged hospitalization. Participants will be enrolled into an 8-week mobile-app based contingency management intervention.
Study: NCT04894305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered as IM injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered as IM injection.
Study: NCT05708638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual anesthesia induction
Description: In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia induction with Target controlled infusions (TCI)
Description: Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
Study: NCT05966272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: single dose
Study: NCT06654960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection single dose.
Study: NCT05966272

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 injection Placebo
Description: single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 injection Placebo
Description: single dose
Study: NCT06654960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride tablets
Description: Metformin Hydrochloride tablets 500mg.